VYXEOS studied in adults with newly-diagnosed t-AML or AML-MRC

A diagnosis of t-AML or AML-MRC included1,2: 309 AML patients
de novo AML with MDS-related cytogenetic abnormalities
Cytogenetic abnormalities characteristic of myelodysplasia based on 2008 WHO criteria
25%
AML with an antecedent hematological disorder 54%
Therapy-related AML
Prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease
20%

In the VYXEOS Phase 3 trial, 15% of patients had a FLT3 gene mutation (n=43/279) and 9% had an NPM1 gene mutation (25/283)1

Patient characteristics were similar across the treatment arms1

Patient and disease characteristics1,3 VYXEOS (n=153)
n (%)
7+3a (n=156)
n (%)
Male/female 94/59 (61/39) 96/60 (62/38)
Median age (range) 68 (60, 75) 68 (60, 75)
ECOG
PS 0-1 138 (90) 134 (86)
PS 2 15 (10) 22 (14)
Cytogenetic risk
Favorable 7 (5) 5 (3)
Intermediate 64 (42) 58 (38)
Poor 72 (47) 83 (53)
  1. Cytarabine and daunorubicin.